Geode Capital Management LLC Boosts Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Geode Capital Management LLC lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 591,631 shares of the company’s stock after purchasing an additional 11,411 shares during the period. Geode Capital Management LLC owned about 2.06% of Krystal Biotech worth $107,714,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Segall Bryant & Hamill LLC increased its stake in Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after buying an additional 122,407 shares in the last quarter. State Street Corp boosted its stake in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Krystal Biotech by 1,972.0% during the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock worth $22,674,000 after purchasing an additional 117,510 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after purchasing an additional 103,928 shares during the last quarter. Finally, Braidwell LP lifted its holdings in Krystal Biotech by 57.4% in the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

KRYS stock opened at $156.64 on Thursday. The firm has a market cap of $4.51 billion, a PE ratio of 88.50 and a beta of 0.80. Krystal Biotech, Inc. has a one year low of $107.50 and a one year high of $219.34. The firm’s 50 day moving average price is $180.70 and its 200-day moving average price is $185.17.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.67) EPS. Equities research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of research reports. Chardan Capital reaffirmed a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday. Finally, Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and an average target price of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).